PARIS, France, June 20, 2022 at 8:30 a.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today oday that during its Combined Annual General Meeting on Friday, June 17, most of the resolutions proposed by its Board of Directors have been adopted.
• Pharnext shareholders approved the 2021 financial statements and most of the resolutions at its Annual General Meeting
• The cooptation of Dr. James Kuo to the Board of Directors brings key experience in terms of strategy